Literature DB >> 32741961

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).

Meral Beksac1, Nicolaus Kröger2, Jennifer L Byrne3, Arnold Ganser4, Zeynep Arzu Yeğin5, Stefan Schönland6.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32741961     DOI： 10.1038/s41409-020-01010-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.

Authors:  Klaus Hirschbühl; Myriam Labopin; Mohamed Houhou; Ludovic Gabellier; Hélène Labussière-Wallet; Bruno Lioure; Dietrich Beelen; Jan Cornelissen; Gerald Wulf; Pavel Jindra; Hervé Tilly; Jakob Passweg; Riita Niittyvuopio; Gesine Bug; Christoph Schmid; Arnon Nagler; Sebastian Giebel; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-12-09       Impact factor: 5.483

Review 2.  Myeloma kidney: improving clinical outcomes?

Authors:  Richard Haynes; Nelson Leung; Robert Kyle; Christopher G Winearls
Journal:  Adv Chronic Kidney Dis       Date:  2012-09       Impact factor: 3.620
  2 in total
  1 in total

1.  Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.

Authors:  John A Snowden; Isabel Sánchez-Ortega; Selim Corbacioglu; Grzegorz W Basak; Christian Chabannon; Rafael de la Camara; Harry Dolstra; Rafael F Duarte; Bertram Glass; Raffaella Greco; Arjan C Lankester; Mohamad Mohty; Bénédicte Neven; Régis Peffault de Latour; Paolo Pedrazzoli; Zinaida Peric; Ibrahim Yakoub-Agha; Anna Sureda; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2022-05-19       Impact factor: 5.174
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.